Lung cancer remains the leading cause of cancer mortality worldwide, with 1.4 million deaths per year. Non--small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases. Upon initial diagnosis, approximately 25%--30% of NSCLC patients present with locally advanced disease, whereas 40%--50% present with metastatic disease[@b1],[@b2]. The third-generation platinum-based doublet chemotherapy (PBC) has long been considered the standard care for advanced NSCLC patients with a good performance status (PS)[@b3]. Although 70%--80% of patients experience clinical benefit after undergoing first-line chemotherapy, the overall survival (OS) remains disappointing, with a 5-year survival rate of less than 1%[@b4]. The OS was 8--10 months, and the 1-year survival rate was 30%--35%[@b5]. Different PBC combinations involving paclitaxel, gemcitabine, vinorelbine, and docetaxel have shown equal efficacies but distinct toxicity profiles in clinical trials[@b5],[@b6]. In addition to the medicine mentioned above, pemetrexed, another cytotoxic drug, was more effective in lung adenocarcinoma than in squamous cell carcinoma with mild toxicity, but the reported survival was still similar to the previously reported result (about 10 months)[@b7],[@b8].

In recent years, advances in targeted therapy have provided new treatment options. Small-molecule tyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor (EGFR), such as gefitinib and erlotinib, have shown antitumor activity in patients with advanced NSCLC, especially those with *EGFR* mutation. A Japanese study compared survival before and after gefitinib treatment in patients with advanced NSCLC and showed that OS was significantly prolonged in patients after gefitinib treatment[@b9].

In most clinical trials about advanced NSCLC during the last decade, monotherapy with either EGFR-TKIs or chemotherapy was administered as a salvage regimen in post-study treatment, though to different extents. The reported OS varied in these trials. Notably, there was no significant difference in patient selection, and the trials were conducted within a relatively short time for an individual patient. Thus, the variance in survival time was likely due to differences in the proportion of patients who underwent post-study treatment[@b10]. Similarly, in a research involving patients with colorectal cancer, the percentage of patients who received fluorouracil-leucovorin, irinotecan, and oxaliplatin (first- or second-line and third-line) was positively correlated with the reported median survival[@b10],[@b11]. However, to our knowledge, no similar study has been conducted in NSCLC. Hence, our study was undertaken to determine the impact of both PBC and EGFR-TKIs on OS in phase III clinical trials of advanced NSCLC.

Materials and Methods {#s2}
=====================

Literature search {#s2a}
-----------------

To ensure all relevant studies (randomized controlled trials) on the topic were retrieved, we used a broad search strategy with key words related to lung cancer. Using the search terms "non--small cell lung cancer," "lung adenocarcinoma," or "lung squamous carcinoma," we identified all related clinical trials of NSCLC published within the past 12 years (January 2001 to February 2012) from PubMed and EMBASE. All results were limited to phase III randomized controlled clinical trials published in English. We also searched the reference lists of articles and reviews.

Literature selection {#s2b}
--------------------

Two reviewers screened all literature independently to verify compliance with the predetermined inclusion criteria. When there were disagreements between the two reviewers, a third reviewer was involved to facilitate consensus.

The inclusion criteria were as follows: (1) the study was a randomized controlled trial; (2) the patients enrolled were \>18 years with pathologically proven advanced NSCLC, and the majority had a baseline Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0--1 (PS = 2 in less than 20% of the patients); (3) the OS was reported, and the percentage of patients treated with both PBC and EGFR-TKIs anytime during the course of treatment was available in the papers; and (4) the patients enrolled were from the general population and not selected on the basis of molecular status (to guarantee homogeneity).

The following trials were excluded: (1) trials involving only patients over 70 years of age or patients previously exposed to other antitumor treatments for an indeterminate time, and (2) trials comparing the combination of chemotherapy and EGFR-TKIs with chemotherapy alone. However, trials comparing chemotherapy and the combination of chemotherapy and other targeted agents such as cetuximab, bevacizumab, vadimezan, and bexarotene were included.

Data collection and analysis {#s2c}
----------------------------

The following data were collected from each selected study: first authors, publication year, study regimens, number of patients, median age, tumor stage, percentage of Asian and Caucasian subjects, percentage of female subjects, tumor pathologic type (proportions of adenocarcinoma and squamous carcinoma), PS, percentage of patients treated with both PBC and EGFR-TKIs, OS, and median progression-free survival (PFS). OS was calculated from the time of first-line treatment, which meant that the patients in the trials should be chemo-naïve.

Statistical analysis {#s2d}
--------------------

Correlation between the percentage of patients receiving both PBC and EGFR-TKIs and the OS was examined using linear regression analysis. For sensitivity analysis, a weighted regression was performed, with weight proportional to the trial\'s sample size. Trials were also divided on the basis of the primary population enrolled---Asian or non-Asian (primarily Caucasian)---by determining the country in which the study was conducted or the proportion of patients of different races. Correlation between the percentage of patients treated with both PBC and EGFR-TKIs and the OS among different ethnicities was determined using the same weighted regression analysis. The influence of patient or tumor characteristics such as sex, PS, ethnicity, tumor histologic subtypes, and tumor stage on OS, PFS, and response rate was also examined with student *t* test or chi-square test. *P* values \<0.05 were considered statistically significant, and all reported *P* values were two-sided. All statistical analyses were performed with STATA SE 10.0 package (StataCorp, College Station, TX, USA).

Results {#s3}
=======

Characteristics of the selected studies {#s3a}
---------------------------------------

Our literature search yielded 350 trials, of which 303 were excluded and 47 were considered potentially relevant. The remaining 47 trials were retrieved for more detailed evaluation. Of these, 21 were excluded for the following reasons: 14 trials were second- or third-line treatments, and the OS was not calculated from first-line treatment; and 7 trials failed to provide survival time or information about the patients receiving TKIs. Upon further analysis of the remaining 26 trials, 11 were excluded: 2 focused on patients over 70 years of age, 4 (OPTIMAL, NEJ002, EURATAC, and WJTOG3405) on patients with *EGFR* mutations, and 5 on the combination of chemotherapy and TKIs. Thus, 15 trials, which involved 11,456 adult patients in 32 arms, met all of the inclusion criteria and were used in our study. The flowchart of trial selection is shown in [**Figure 1**](#cjc-33-02-105-g001){ref-type="fig"}.

![Flow chart showing the process of trial selection in patients with non--small cell lung cancer (NSCLC).\
OS, overall survival; PBC, platinum-based doublet chemotherapy; TKIs, tyrosine kinase inhibitors.](cjc-33-02-105-g001){#cjc-33-02-105-g001}

For patients in the 15 selected trials, the median age was 61 years (range, 56--65 years), and the majority (range, 82%--100%) had a PS of 0--1. Six trials were performed in predominantly Asian populations, whereas 9 were performed in non-Asian (predominantly Caucasian) populations. The basic characteristics of the 15 trials are shown in [**Table 1**](#cjc-33-02-105-t01){ref-type="table"}.

###### Characteristics of the trials included in the analysis

  First author/year                       Study regimens        No. of Pts   PS (%)   Median age (years)   Stage (%)   PFS (months)   Female (%)         
  --------------------------------- -------------------------- ------------ -------- -------------------- ----------- -------------- ------------ ------ ------
  Mok TS/2010 [@b23]                        Gefitinib              609         90             10              57           24.6          75.4      5.7    79.5
                                                TC                 608        89.3           10.7             57           23.8          76.2      5.8    79.1
  Okamoto I/2010 [@b31]                         TC                 281        100             0               63           24.2          75.8      4.8    23.5
                                        Carboplatin + S-1          282        100             0               64           24.1          75.9      4.1    23.0
  Kubota K/2008 [@b32]               GN followed docetaxel^a^      196        100             0               64           17.0           83       5.5    27.0
                                                TC                 197        100             0               65           17.0           83       5.8    31.0
  Ohe Y/2007 [@b33]                             IP                 145        100             0               62           21.4          78.6      4.7    33.1
                                                TC                 145        100             0               63           19.3          80.7      4.5    31.7
                                                GP                 146        100             0               61           20.5          79.5      4.0    30.8
                                                NP                 145        100             0               61           17.9          82.1      4.1    30.3
  Kubota K/2004 [@b34]                          DP                 151         96             4               63            0            100        \-    35.8
                                      Vindesine + cisplatin        151        96.7           3.3              64            0            100        \-    31.8
  Han JY/2012 [@b24]                        Gefitinib              159        91.2           8.8              57           10.7          89.3      5.8    88.0
                                                GP                 150        90.7           9.3             56.5          9.3           90.7      6.4    89.3
  Lara PN Jr/2011 [@b35]                  TC + vadimezan           649        99.7            \-              62           8.2           91.8      5.5    37.9
                                           TC + placebo            650        98.8            \-              61           9.1           90.9      5.5    37.7
  Reck M/2010 [@b36]                       Placebo + GP            347        100             0               59           23.0           77       6.1    36.0
                                       Bevacizumab7.5 + GP         345        100             0               57           22.0           78       6.7    35.0
                                        Bevacizumab15 + GP         351        100             0               59           23.0           77       6.5    38.0
  Lynch TJ/2010 [@b37]                      TC + C225              338         98             2               64           12.0           88       4.4    43.0
                                                TC                 338         99             1               65           14.0           86       4.24   40.0
  Pirker R/2009 [@b38]                    NP + cetuximab           557         83             17              59           6.0            94       4.8    31.0
                                                NP                 568         82             18              60           6.0            94       4.8    29.0
  Tan EH/2009 [@b39]                            NP                 194        62.1           37.9            59.4          19.5          80.5      4.9    26.8
                                                DP                 196        62.3           37.7            62.1          15.2          84.8      5.1    23.6
  Scagliotti GV/2008 [@b8]                      GP                 830        99.9            NA             61.1          24.3          75.7      5.1    29.9
                                                AP                 839        99.8            NA              61           23.8          76.2      4.8    29.8
  Ramlau R/2008 [@b40]                   Bexarotene + NP           311        100             0               61           17.0          83.0      4.3    28.0
                                                NP                 312        100             0               61           19.0          81.0      5.0    28.0
  Blumenschein GR Jr /2008 [@b41]        TC + bexarotene           306        100             0               63           13.0          87.0      4.1    34.0
                                                TC                 306        100             0               63           13.0          87.0      4.9    34.0
  Sandler A/2011 [@b42]                  TC + bevacizumab          417        100             0               NA           22.0          78.0      6.2    50.0
                                                TC                 433        100             0               NA           26.0          74.0      4.5    42.0

Pts, patients; PS, performance status; PFS, median progression-free survival; TC, paclitaxel + carboplatin; GN, gemcitabine + vinorelbine; IP, irinotecan + cisplatin; GP, gemcitabine + cisplatin; NP, vinorelbine + cisplatin; DP, docetaxel + cisplatin; AP, pemetrexed + cisplatin; NA, not available. ^a^This arm was excluded, because the percentage of patients treated with both platinum-based doublet chemotherapy (PBC) and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) was unknown.

Correlation between trial characteristics and treatment results {#s3b}
---------------------------------------------------------------

The impact of trial characteristics on OS, PFS, and response rate is summarized in [**Table 2**](#cjc-33-02-105-t02){ref-type="table"}. Trials primarily involving Asian populations showed longer OS than did trials in non-Asian populations (*P* \< 0.001). Similarly, the response rate to first-line treatment in Asian populations was also better than that in non-Asian populations (*P* = 0.007). In study arms with a larger proportion of adenocarcinomas, the OS and PFS were longer and the response rate was higher than those in arms with a smaller proportion of adenocarcinomas (*P* \< 0.001, *P* = 0.017, and *P* = 0.012, respectively). The proportion of stage IV cases enrolled had no impact on OS (*P* = 0.560), PFS (*P* = 0.760), or response rate (*P* = 0.950). Most of the trials included patients with a PS of 0--1, with only a small portion having a PS of 2. The small proportion of patients with PS = 2 had no impact on the OS (*P* = 0.170) but did affect the response rate (*P* = 0.014). The trials with higher proportion of female subjects showed longer PFS (*P* = 0.005), but the OS and response rates were similar.

###### The influence of trial characteristics on treatment results

  Characteristic of the trials               No. of arms   OS^c^ (months)     *P*     PFS^c,d^ (months)    *P*    Response rate^c^ (%)    *P*
  ----------------------------------------- ------------- ---------------- --------- ------------------- ------- ---------------------- -------
  Ethnicity                                                                                                                             
   Asian population                              13          15.1 ± 4.1     \<0.001       5.1 ± 0.9       0.832        34.7 ± 9.2        0.007
   Non-Asian population (Caucasian)              19          10.8 ± 1.8                   5.1 ± 0.8                    26.6 ± 6.8       
  Proportion of females^a^                                                                                                              
   \< 34%                                        16          11.5 ± 2.0      0.11         4.8 ± 0.5       0.005        29.7 ± 5.5        0.92
   ≥34%                                          16          13.6 ± 4.5                   5.5 ± 0.9                   30.0 ± 11.3       
  Proportion of adenocarcinomas^a^                                                                                                      
   \< 68%                                        16          10.4 ± 1.9     \<0.001       4.8 ± 0.5       0.017        26.1 ± 6.1        0.012
   ≥68%                                          16          14.6 ± 3.8                   5.4 ± 0.9                    32.6 ± 9.5       
  Proportion of patients with PS ≥2^b^                                                                                                  
   0                                             17          11.9 ± 2.3      0.17         5.0 ± 0.9       0.56         26.9 ± 7.6        0.014
   \> 0                                          11          13.9 ± 5.3                   5.2 ± 0.7                    35.5 ± 9.4       
  Proportion of patients with stage IV^a^                                                                                               
   \< 83%                                        16          12.9 ± 2.6      0.56         5.2 ± 0.9       0.74         30.0 ± 6.7        0.95
   ≥83%                                          16          12.1 ± 4.6                   5.1 ± 0.7                   29.8 ± 10.8       

OS, overall survival; PFS, progression-free survival; PS, performance status. ^a^ The characteristics of all study arms were divided into two groups according to the median and then were compared. ^b^ Most of the trials had enrolled patients with PS 0-1. Two trials did not provide the data of patients with PS ≥2. ^c^ All the values are presented as mean ± standard deviation. ^d^ In one of the trials (two arms), there were no PFS reported.

Correlation between the percentage of patients treated with PBC and EGFR-TKIs and the OS {#s3c}
----------------------------------------------------------------------------------------

Plotting the data collected from the studies shown in [**Table 3**](#cjc-33-02-105-t03){ref-type="table"}, we found that the percentage of patients who underwent both PBC and EGFR-TKIs during the course of treatment was positively correlated with the reported OS (*r* = 0.797, *P* \< 0.001; [**Figure 2**](#cjc-33-02-105-g002){ref-type="fig"}). The trials with a higher proportion of patients treated with both PBC and EGFR-TKIs during the course of treatment showed longer OS. We further divided these trials by race group---Asian and non-Asian (predominantly Caucasian). We found that the correlation between the percentage of patients who underwent both PBC and EGFR-TKIs and the OS was strong in the 6 Asian trials (*r* = 0.936, *P* \< 0.001; [**Figure 3**](#cjc-33-02-105-g003){ref-type="fig"}) but not in the 9 non-Asian trials (*r* = 0.116, *P* = 0.588; [**Figure 4**](#cjc-33-02-105-g004){ref-type="fig"}).

In the non-Asian trials, the percentage of patients treated with both PBC and EGFR-TKIs was less than 30%. The correlation of that percentage with OS was not statistically significant, but the OS varied from 8.4 months to 13.6 months. OS did not differ significantly between study regimens---third-generation PBC and the combination of chemotherapy and targeted agents (*P* = 0.356).

Discussion {#s4}
==========

Our research demonstrated a strong correlation between the percentage of patients treated with both PBC and EGFR-TKIs and OS. This finding highlights the importance of making both PBC and EGFR-TKIs available to patients with advanced NSCLC during the course of treatment to achieve maximal survival benefit. In most trials included in our analysis, PBC was first-line treatment and EGFR-TKIs were second-line or third-line. EGFR-TKIs were taken as a salvage treatment. Here, we found that the specific salvage therapy patients underwent impacted the OS. Our findings suggest that patients who undergo first-line PBC need EGFR-TKIs as second-line or third-line treatment to maximize the survival benefit.

After EGFR-TKIs were approved for advanced NSCLC, the OS of advanced NSCLC patients increased[@b9]. In the BR.21[@b12] and TRUST[@b13] studies, erlotinib monotherapy had better efficacy and was safer in second-line or third-line treatment than placebo. Recently, the Tailor study indicated that patients with wild-type *EGFR* who underwent previous treatment did not obtain a PFS benefit from second-line erlotinib compared with docetaxel[@b14]. Furthermore, the impact of second-line treatment with EGFR-TKI on NSCLC patient survival was not yet known.

It is now apparent that *EGFR* mutation status is a determinant of survival benefit from TKI treatment. Currently, erlotinib is recommended as first-line treatment for NSCLC patients with *EGFR* mutation. Gefitinib is also a recommended option for Asian patients. Riely *et al*.[@b15] reported that the overall *EGFR* mutation rate in non-selected cases of NSCLC was 16.7%. *EGFR* mutations are also more prevalent in Asian patients compared with Caucasian patients (30.6% vs. 7.6%)[@b16]. Most of the trials in our study did not report the *EGFR* mutation rate, likely because this predictive factor was not yet confirmed when the trials were conducted. Nevertheless, these findings suggest that the more patients receiving EGFR-TKIs after chemotherapy in the trial, the higher the probability that patients with *EGFR* mutation benefit from treatment. Furthermore, the high prevalence of *EGFR* mutation in Asian populations may explain the strong correlation between the percentage of patients treated with both PBC and EGFR-TKIs and OS which was observed in our study. By contrast, the correlation was not as strong in Caucasian populations, in which *EGFR* mutation is less prevalent. Notably, the percentage of patients treated with both PBC and EGTR-TKIs was less than 30% in the predominantly Caucasian trials, which may also underlie the weak correlation.

The discrepancy of the chemotherapy effect in different races was reported in another meta-analysis, which compared the survival of patients with advanced NSCLC. In that study, the median OS with third-generation PBC in Asian and Caucasian trials was 11.3 and 9.5 months, respectively[@b17],[@b18]. In a historical comparison, the presence of *EGFR* mutation was reported to be an independent, favorable prognostic factor for advanced NSCLC patients. Without EGFR-TKI treatment, patients with *EGFR* mutation still showed longer survival than those with wild-type *EGFR*[@b9]. Comparing [**Figures 3**](#cjc-33-02-105-g003){ref-type="fig"} and [**4**](#cjc-33-02-105-g004){ref-type="fig"}, we found that at 0% of patients with both treatments, the median OS was 10.8 months in Asian trials and 8.8 months in non-Asian (predominantly Caucasian) trials. In fact, at the point of 0, the survival outcome was mainly an effect of chemotherapy. Our finding was consistent with the results of the meta-analysis.

We did not extrapolate the predicted OS if 100% of patients underwent both PBC and EGFR-TKIs, because this value was outside the range of data in our linear regression model. Instead, we used other available data to prove the regression model. We analyzed 6 clinical trials in which first-line EGFR-TKIs was compared with chemotherapy. Of these trials, 4 were not included in our correlation analysis because the patients were selected according to molecular status (positive for *EGFR* mutation)[@b19]--[@b22]. The other 2 trials---IPASS[@b23] and First-signal[@b24]---were included in our correlation analysis. Here, however, we only analyzed the subgroup of patients with *EGFR* mutation. These studies had significant overlap between EGFR-TKIs and PBC treatment regimens, and therefore, the percentage of patients treated with both PBC and EGFR-TKIs was high. Because all patients were positive for *EGFR* mutation, the prognosis should be better than the prognosis for the Asian population. Based on our mathematic equation of regression in Asian populations and the available data, we compared the calculated OS of these trials with the reported results ([**Table 4**](#cjc-33-02-105-t04){ref-type="table"}). Theoretically, the reported OS should be longer than the calculated OS, and we found that the result was consistent with our hypotheses.

###### Correlation between percentage of patients treated with both PBC and EGFR-TKIs during the course of the disease and the reported OS

  First author/year                  No. of Pts (%)   Response rate (%)   Reported OS (months)   Asian (%)   Caucasian (%)   Adenocarcinoma (%)   Squamous (%)  
  --------------------------------- ---------------- ------------------- ---------------------- ----------- --------------- -------------------- -------------- ------
  Mok TS/2010 [@b23]                      609              (64.5)                 43.0             18.8          99.7                NR               95.4        0
                                          608              (51.5)                 32.2             17.3          99.8                NR               97.2        0
  Okamoto I/2010 [@b31]                   281              (24.0)                 29.0             13.3           100                0                69.4       30.6
                                          282              (27.2)                 20.4             15.2           100                0                69.1       30.9
  Kubota K/2008 [@b32]                    196                NA                   25.0             13.6           100                0                 66         23
                                          197              (40.0)                 37.0             14.1           100                0                 76         15
  Ohe Y/2007 [@b33]                       145               (7.6)                 31.0             13.9           100                0                83.4        11
                                          145               (6.2)                 32.4             12.3           100                0                71.7       21.4
                                          146              (12.3)                 30.1              14            100                0                 74        19.9
                                          145               (8.3)                 33.1             11.4           100                0                75.2        20
  Kubota K/2004 [@b34]                    151               (3.0)                  25              11.3           100                0                79.5       11.3
                                          151               (1.0)                  37               9.6           100                0                68.2       21.9
  Han JY/2012 [@b24]                      159              (65.0)                 55.4             22.3           100                0                100         0
                                          150              (75.0)                 46.0             22.9           100                0                100         0
  Lara PN Jr/2011 [@b35]                  649              (20.5)                 24.7             13.4           25                71.5              66.5       20.3
                                          650              (21.4)                 24.6             12.7          25.2               71.5              67.1       20.5
  Reck M/2010 [@b36]                      347              (25.0)                 21.6             13.1            8                 92                82         NR
                                          345              (29.0)                 37.8             13.6            9                 91                85         NR
                                          351              (24.0)                 34.6             13.4            9                 91                85         NR
  Lynch TJ/2010 [@b37]                    338              (25.1)                 25.7             9.69            2                 88                51         20
                                          338              (22.8)                 17.2             8.38            3                 89                54         19
  Pirker R/2009 [@b38]                    557              (17.0)                 36.0             11.3           11                 84                46         34
                                          568              (27.0)                 29.0             10.1           10                 85                49         33
  Tan EH/2009 [@b39]                      194              (15.5)                 31.2              9.9            0                100               41.6       34.2
                                          196              (15.8)                 29.6              9.8            0                100               39.3       33.5
  Scagliotti GV/2008 [@b8]                830              (22.5)                 28.2             10.3          12.1               78.8              47.6       26.5
                                          839              (24.9)                 30.6             10.3          13.5               77.6              50.6       28.3
  Ramlau R/2008 [@b40]                    311              (11.0)                 16.7              8.7            1                 89                39         38
                                          312              (13.0)                 24.4              9.9            1                 92                41         36
  Blumenschein GR Jr /2008 [@b41]         306              (22.0)                 19.3              8.5           NR                 88                55         20
                                          306              (27.0)                 23.5              9.2           NR                 89                50         21
  Sandler A/2011 [@b42]                   417              (13.7)                 35.0             12.3          25.0               91.0              88.0       20.3
                                          433              (17.8)                 15.0             10.3          25.2               90.0              88.0       20.5

Pts, patients; PS, performance status; OS, overall survival; NA, not available. NR, not reported.

The patients who most benefited from EGFR-TKIs were those with *EGFR* mutation. *EGFR* mutation test is now recommended for NSCLC patients[@b25]. However, the recommendation has not been well applied in China. Indeed, only 7.8% of patients with advanced NSCLC were tested for *EGFR* mutation, according to a national survey of medical treatment status for NSCLC conducted in 12 Chinese cities[@b26]. This low rate was mainly due to inadequate samples and high cost for testing, as well as limited testing technology. Nevertheless, the survey indicated that EGFR-TKIs were frequently used for salvage treatment.

The results of our present study show that it is important to make both PBC and EGFR-TKIs available for advanced NSCLC patients. In addition, sequential treatment with chemotherapy and EGFR-TKIs, rather than concurrent treatment, provided a survival benefit for patients. This is consistent with results from several trials[@b27]--[@b29], which show that concurrent treatment was not superior to chemotherapy alone. One possible reason for the failure of concurrent treatment is that the patients were not screened and selected, as there was no available test with which to identify those likely to benefit from EGFR-TKIs at that time[@b30]. Notably, these concurrent treatment trials[@b25]--[@b27], such as TRIBUTE, INTACT 1 and INTACT 2, were conducted in non-Asian countries, where the *EGFR* mutation rate is low. Another reason might be an unidentified negative interaction when EGFR-TKIs are given concurrently with chemotherapy[@b27].

![Linear regression curve showing positive correlation between the percentage of patients treated with both PBC and EGFR-TKIs during the course of treatment and the OS (*r* = 0.797, *R*^2^ = 0.636, *P* \< 0.001) in all selected trials.\
Mathematic equation of regression (based on a weighted model): OS (months) = 8.01 + 16.7 × (percentage of patients treated with both PBC and EGFR-TKIs).](cjc-33-02-105-g002){#cjc-33-02-105-g002}

![Linear regression curve showing positive correlation between the percentage of patients treated with both PBC and EGFR-TKIs during the course of treatment and the OS (*r* = 0.936, *R*^2^ = 0.876, *P* \< 0.001) in Asian trials.\
Mathematic equation of regression (based on a weighted model): OS (months) =10.82 + 13.42 × (percentage of patients treated with both PBC and EGFR-TKIs).](cjc-33-02-105-g003){#cjc-33-02-105-g003}

![Linear regression curve showing no obvious correlation correlation between the percentage of patients treated with both PBC and EGFR-TKIs during the course of treatment and the OS in non-Asian (predominantly Caucasian) trials (*r* = 0.116, *R*^2^ = 0.013, *P* = 0.588).\
Mathematic equation of regression (based on a weighted model): OS (months) = 8.83 + 10.52 × (percentage of patients treated with both PBC and EGFR-TKIs).](cjc-33-02-105-g004){#cjc-33-02-105-g004}

###### Baseline characteristics of the six trials comparing EGFR-TKIs with chemotherapy for patients with previously untreated NSCLC with mutated *EGFR*

  Trial             First author/year          Regimens       No. of patients (%)   Reported OS (months)   Calculated OS (months)  
  -------------- ------------------------ ------------------ --------------------- ---------------------- ------------------------ ------
  IPASS             Mok TS/2009[@b23]      Gefitinib 250 mg           132                  \(75\)                   21.6            20.9
                                                  TC                  129                  (64.3)                   21.9            19.4
  First SIGNAL      HAN JY/2012[@b24]      Gefitinib 250 mg           26                     NR                     30.6             NR
                                                  GP                  16                     NR                     26.5             NR
  NEJ 002         Maemondo M/2011[@b22]    Gefitinib 250 mg           114                  (67.5)                   30.5            19.8
                                                  TC                  114                  (94.6)                   23.6            23.5
  WJTOG3405       Mitsudomi T/2011[@b20]   Gefitinib 250 mg           86                   \(61\)                    36             19.0
                                                  DP                  86                   \(91\)                    39             23.5
  OPTIMAL           Zhou CC/2011[@b19]     Erlotinib 150 mg           82                   \(52\)                   22.7            17.8
                                                  GC                  72                   \(71\)                   28.9            20.3
  EURTAC           Rosell R/2012[@b21]     Erlotinib 150 mg           77                     NR                     19.3             NR
                                             Standard PBC             76                   \(76\)                 19.5^a^           21.0

TC, paclitaxel + carboplatin; GP, gemcitabine + cisplatin; DP, docetaxel + cisplatin; GC, gemcitabine + carboplatin; OS, overall survival; NR, not reported. ^a^ The reported OS was not mature.

There was an inherent bias in our analysis. One might argue that patients who live longer have greater opportunity to be treated with both PBC and EGFR-TKIs. In fact, all the trials included in our study were conducted after the approval of TKIs, after which the survival of advanced NSCLC did improve[@b9]. In all trials in our study, the median PFS of patients who underwent first-line chemotherapy was 4--6 months[@b29]--[@b42]. Hence, most patients had the chance to undergo second- or third-line treatment after disease progression. Our findings suggest that EGFR-TKIs should be considered an option. Nevertheless, this study was not conducted as a formal meta-analysis, as only reported data, and not individual patient data, were used for analysis. Hence, the study should be taken as hypothesis generating. However, we provide evidence in support of our hypothesis that the percentage of patients with both PBC and EGFR-TKIs positively correlated with OS using other data from clinical trials.

In conclusion, we have found a strong relationship between the percentage of patients treated with sequential treatment with PBC and EGFR-TKIs and OS. The differences in the strength of the correlation in Asians and Caucasians might be caused by the distinct *EGFR* mutation rates in each population. Our results support the concept of making these two treatments available to NSCLC patients over the whole course of treatment to maximize the survival benefit.

[^1]: Jian-Wei Zhang and Yuan-Yuan Zhao contributed equally to this work.
